AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive ...
Panelists discuss how current risk stratification systems, particularly the European Leukemia Net 2022 classification for intensive therapy and the 2024 classification for lower intensity treatments, ...
Accurate risk assessment is a highly technical process for patients with acute myeloid leukemia (AML). A new tool could help make such assessments available even when patients can’t get to a specialty ...
—Patients with acute myeloid leukemia undergoing intensive chemo may be at a higher risk of a cardiovascular event if they harbor 2 or more mutations related to clonal hematopoiesis of indeterminate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results